CABA
Cabaletta Bio, Inc. Common StockstockNASDAQ
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.33 | 2026-11-12 | -20.30% | 8.591 |
| 1M | 1.48 | 2026-10-19 | -28.38% | 3.106 |
| 3M | 3.10 | 2026-08-19 | -65.81% | 2.986 |
| 6M | 3.27 | 2026-05-19 | -67.58% | 2.129 |
| 1Y | 2.24 | 2025-11-19 | -52.68% | 1.895 |
| 2Y | 2.54 | 2024-11-19 | -58.27% | — |
| 5Y | 11.98 | 2021-11-19 | -91.15% | 1.495 |
Cabaletta Bio, Inc. Common Stock (NASDAQ:CABA) stock price today is $1.06, and today's volume is 4,159,201. CABA is up 3.922% today. The 30 day average volume is 4.82M. CABA market cap is $228.66M with 215.72M shares outstanding.